Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Adjuvants are important components of cancer vaccines because they enhance immune responses to vaccination. However, adjuvants licensed for clinical use, e. g. aluminum salts, fail to stimulate an effective immune response. Research and development of new adjuvants with combined functions, including immune stimulation and antigen delivery, are a vital task for antitumor immunotherapy. Clinical trials of immune stimulating compounds, in particular Toll-like receptor (TLR) ligands, reveal their therapeutic potential as both antitumor agents and vaccine adjuvants.
Publisher
Publishing House ABV Press
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献